Exploiting targeted therapy-induced ATM dependence in residual lung tumors
Ended Project Grant Awarded Last action
- Award ID
- W81XWH2110362
- Recipient
-
Duke University UEI TP7EK8DZV6N5
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $547,664
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date
- Place of performance
- Durham, NC 27708, USA
Award details come from USAspending.gov.
About this award
The Department of the Army Medical Command awarded Duke University a $547,664 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from June 2021 to May 2023 to exploit targeted therapy-induced ATM dependence in residual lung tumors. Through this award, Duke University researchers will investigate medical solutions for the battlefield by transforming health care for Service Members and the American public through innovative and impactful research into targeted lung cancer therapies. The research aims to develop new treatment approaches that leverage tumors' reliance on specific genes to overcome resistance to initial therapies and eliminate residual disease.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $547,664 |
Quick answers
Who received award W81XWH2110362?
W81XWH2110362 was awarded to Duke University by Medical Command (Department of the Army) on June 1, 2021.
How much is award W81XWH2110362 worth?
$547,664 has been obligated on W81XWH2110362.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award